PRESS-NEWS.org - Press Release Distribution
FREE PRESS RELEASES DISTRIBUTION

High-dose interleukin-2 effective in mRCC pre-treated with VEGF-targeted therapies

ESMO Symposium on Immuno-Oncology 2014

High-dose interleukin-2 effective in mRCC pre-treated with VEGF-targeted therapies
2014-11-24
(Press-News.org) VIDEO: High-dose interleukin-2 can be effective in selected metastatic renal cell cancer patients pre-treated with VEGF-targeted agents, reveals research presented today at the ESMO Symposium on Immuno-Oncology in Geneva, Switzerland....
Click here for more information.

Lugano/Geneva, Switzerland, 24 November 2014 - High-dose interleukin-2 can be effective in selected metastatic renal cell cancer patients pre-treated with VEGF-targeted agents, reveals research presented today at the ESMO Symposium on Immuno-Oncology in Geneva, Switzerland.

Lead author Dr Manon Evans, research fellow at the Christie Hospital in Manchester, UK, said: "Despite the wide and increasing range of therapies available, the management of metastatic renal cell carcinoma (mRCC) remains challenging. Agents targeting the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways are currently the standard of care. Whilst these therapies are well tolerated and demonstrate impressive response rates, the responses seen are very rarely complete and durable."

She added: "High-dose interleukin-2 (HD-IL2) --a protein that activates the immune system-- can induce durable complete responses in small numbers of patients with mRCC. However, due to significant toxicities, its use remains limited. To date, it has been used as an option in the treatment-naïve population only, with concerns over its efficacy and safety post-VEGF targeted agents."

Given the expanding treatment options now available, selecting the therapy most likely to yield the best long-term response for patients is of increasing importance. Evans continued: "We have previously demonstrated that pre-selecting patients by a combination of clinical and histological criteria can generate impressive results in the treatment-naïve population.1 " Patients were classified as 'Favourable' or 'Other' based on their histological makeup.

The current study is a retrospective analysis of 180 patients treated with HD-IL2 at the Christie NHS Foundation Trust over the past 10 years. The majority were treated in the first-line setting, with a smaller cohort receiving treatment following VEGF-targeted agents. The researchers also investigated whether expression of the biomarker carbonic anhydrase IX (CAIX) correlated with outcome and could potentially be added to the selection criteria for HD-IL2 therapy.

A total of 180 patients with mRCC were treated with HD-IL2, 145 in the treatment-naïve cohort and 35 in the pre-treated cohort. Of these, a total of 158 had 'Favourable' histology of whom over 45% responded with a 23% complete remission rate. Of those achieving a complete response to therapy, over 75% are alive and disease free. The median overall survival in those achieving a complete response has not yet been reached. There was no significant difference in response or survival rate between the two treatment cohorts.

CAIX positivity correlated favourably with response and survival as did disease burden and tolerance of treatment. All patients experienced toxicity as anticipated. The incidence of treatment-related myocarditis was higher in the pre-treated cohort (8.5%) compared to the treatment-naïve group (3.4%).

Evans said: "Our data confirms that there remains a role for HD-IL2 in the management of mRCC and demonstrates, in a selected population, complete responses of over 20%, most of which are durable. In contrast to initial reports, it can be safe and effective in carefully selected patients pre-treated with VEGF-targeted agents with response rates and complete responses similar to first-line therapy. Its application should strongly be considered in both the treatment-naïve and pre-treated population."

She continued: "Outcomes were clearly superior in patients with 'Favourable' histology (incorporating those with solid/alveolar clear cell RCC) but there were rare durable complete remissions in patients with 'Other' histologies and the role of HD-IL2 in this group is less well defined with further assessment required."

Watch the video interview with Prof. John Haanen, Head of Division of Medical Oncology at NKI-AVL, Amsterdam, The Netherlands, commenting on the trial results:

https://www.youtube.com/watch?v=Gr5s8LbkPqU

Commenting on the implications of the findings, Dr Michele Maio, chair of the Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Italy, said: "In this retrospective analysis, the use of intravenous HD-IL2 induced complete responses and long-lasting complete responses not only in patients treated first line but also in patients pre-treated with VEGF inhibitors. Until a few years ago, HD-IL2 was the only alternative for patients with mRCC. Today VEGF inhibitors are commonly used in daily practice but we cannot generally obtain long-term responses or long-term complete responses, which are typical of HD-IL2 and immunotherapy in general."

Maio continued: "The authors found that HD-IL2 seems to work in second line to the same extent as it works in first line. This is important for the treatment algorithm of patients with mRCC. One must now consider HD-IL2 as first- or even second-line treatment in patients with mRCC who have a favourable histology. This means that HD-IL2 is still an important drug to be cleverly utilised in the treatment algorithm of patients with mRCC now that we also have VEGF inhibitors available."

"The treatment algorithm of these patients will change again in the near future," added Maio, "because it will include immune checkpoint blocking antibodies, mainly anti-PD-1 and anti-PD-L1 antibodies, that are being actively developed in clinical trials in renal cell carcinoma. This is an additional form of immunotherapy that hopefully will also contribute to the improved long-term survival of these patients."

Maio concluded: "Until a few years ago we had very limited treatment possibilities for mRCC patients. Now we have confirmation that HD-IL2 is still an important option for patients with a favourable histology. HD IL-2 can be very toxic so this is a strategy that is mainly reserved for patients with a very good performance status and it has to be administered by professionals who are experienced with the drug and its side-effects."

INFORMATION:

Notes to Editors 4O - Evaluating the place of interleukin-2 in the management of metastatic renal cell cancer (mRCC) in the era of targeted therapy". 1 Shablak A, Sikand K, Shanks JH, Thistlethwaite F, Spencer-Shaw A, Hawkins RE. High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer. J Immunother. 2011;34(1):107-112. Session info 4O Friday, November 21, 2014 - 17:25 CET. Disclaimer Information contained in this press release was provided by the abstracts authors and reflects the content of the studies. It does not necessarily express ESMO's point of view. About the European Society for Medical Oncology The European Society for Medical Oncology (ESMO) is the leading European professional organization committed to advancing the specialty of medical oncology and promoting a multidisciplinary approach to cancer treatment and care. ESMO's mission is to advance cancer care and cure through fostering and disseminating good science that leads to better medicine and determines best practice. ESMO's scientific journal, Annals of Oncology, ranks among the top clinical oncology journals worldwide. ESMO events are the meeting place in Europe for medical oncologists to update their knowledge, to network and to exchange ideas. To find out more about ESMO, please visit: http://www.esmo.org http://www.esmo.org

Abstract: 4O EVALUATING THE PLACE OF INTERLEUKIN-2 IN THE MANAGEMENT OF METASTATIC RENAL CELL CANCER (MRCC) IN THE ERA OF TARGETED THERAPY M. Evans1, S. Chow1, V. Galvis1, R. Leach2, E. Keene1, A. Spencer-Shaw1, A. Shablak1, J. Shanks1, F. Thistlethwaite1, R. Hawkins1 1Medical Oncology, The Christie NHS Foundation Trust, Manchester, UNITED KINGDOM, 2The Christie NHS Foundation Trust, Manchester, UNITED KINGDOM

Introduction: Despite the advent of targeted agents for the treatment of mRCC, HD-IL2 is the only licensed agent consistently capable of achieving durable long term remissions. Its role in treatment-naïve patients is well recognised but its efficacy and feasibility after VEGF-targeted therapies is less certain. We present outcomes from our experience of HD-IL2 therapy in both treatment-naïve (Group A) and patients pre-treated with VEGF-targeted therapies (Group B).

Methods: We provide a regional/national treatment service with HD-IL2 for selected patients with mRCC. Selection is based on clinical and histological features as described by Shablak (Shablak et al., J Immunother. 2011; 34(1):107-12). 180 patients were analysed with 145 in Group A (treated 2003-2013) and 35 in Group B (treated 2007-2013). HD-IL2 was administered as per standard dosing and schedule. Clinical records were reviewed retrospectively; survivals were analysed by Kaplan-Meir methods.

Results: The majority of patients had 'Favourable' histology with 89% in Group A and 88% in Group B. As previously reported the outcomes were clearly superior in those with favourable histology but there were rare durable complete remissions in patients with other histologies. Outcomes in patients with 'Favourable' histology were comparable in both populations with overall response rates (ORR) and complete response (CR) rates being 47%,23% (Group A) and 42% 19% (Group B). Most CRs are durable and Median OS in CR patients is not yet reached in either group. All patients experienced expected toxicities associated with treatment. 8 (5.5%) (Group A) and 2 (5.7%)(Group B) of patients were transferred to critical care for invasive monitoring. 5 (3.4%) patients in the treatment-naïve group developed myocarditis vs 3 (8.5%) in the pre-treated group - with one treatment related death in (related to myocarditis).

Conclusions: Our results confirm that HD-IL2 remains an effective first-line treatment in well-selected patients with mRCC providing durable complete remissions in over 20% of patients. While cardiac toxicity appears higher in pretreated patients, HD-IL2 in this setting is effective, tolerable and can produce durable remissions comparable to those seen in the first-line setting. With the introduction of increasing numbers of therapies (including new immune therapies) for the treatment of mRCC it is important to make the best use of all treatments and to combine / sequence therapies to maximise the chance of durable benefits for patients.

Disclosure: All authors have declared no conflicts of interest. Keywords: HD-IL2, interleukin-2, metastatic renal cell cancer

Media contact ESMO Press Office E-mail media@esmo.org


[Attachments] See images for this press release:
High-dose interleukin-2 effective in mRCC pre-treated with VEGF-targeted therapies High-dose interleukin-2 effective in mRCC pre-treated with VEGF-targeted therapies 2

ELSE PRESS RELEASES FROM THIS DATE:

Discovery by NUS researchers contributes towards future treatment of multiple sclerosis

Discovery by NUS researchers contributes towards future treatment of multiple sclerosis
2014-11-24
A multi-disciplinary research team from the National University of Singapore (NUS) has made a breakthrough discovery of a new type of immune cells that may help in the development of a future treatment for multiple sclerosis (MS). Led by Professor Xin-Yuan Fu, Senior Principal Investigator from CSI Singapore and Professor at the Department of Biochemistry at the NUS Yong Loo Lin School of Medicine, and Dr Wanqiang Sheng, post-doctoral fellow at CSI Singapore, the team found that a new type of immune T helper cells named TH-GM cells play a crucial role in the immune system ...

Survivors of childhood eye cancer experience normal cognitive functioning as adults

2014-11-24
(MEMPHIS, Tenn. - November 24, 2014) Most long-term survivors of retinoblastoma, particularly those who had been diagnosed with tumors by their first birthdays, have normal cognitive function as adults, according to a St. Jude Children's Research Hospital study. The research, which appears in the current issue of the journal Cancer, found that the vast majority of survivors work full time, live independently and fulfill other milestones of adult life. The study is the first to examine how adult survivors of retinoblastoma fare cognitively and socially decades after their ...

Important element in the fight against sleeping sickness found

Important element in the fight against sleeping sickness found
2014-11-24
Researchers from Aarhus University have taken an important step in the fight against sleeping sickness, a disease that is a major problem in parts of Africa. According to the World Health Organization (WHO), the disease threatens approximately 60 million people and the treatment options are poor. The deadly disease is caused by a parasite that is transferred to people via the bite of the African tsetse fly. The parasite lives in the bloodstream where it absorbs haemoglobin from human red blood cells. However, if left untreated it can infect the central nervous system ...

Study finds provider-focused intervention improves HPV vaccination rates

2014-11-24
(Boston)--Changing the way doctors practice medicine is difficult, however a new study has shown that combining traditional education with quality improvement and incentives improves Human Papilloma virus (HPV) vaccination rates in boys and girls. The study, which appears on-line in the journal Vaccine, has the potential to produce sustained improvements in these vaccination rates. Every year, approximately three million Americans seek treatment for HPV related diseases. Twenty-seven thousand Americans develop HPV-related cancer while more than 5,000 people die from this ...

'Good fat' could help manage type 2 diabetes

2014-11-24
A special type of fat found in some people could be used to manage type 2 diabetes. Scientists from Monash University and Stockholm University have discovered that brown fat, nicknamed the 'good fat' because it warms up the body in cold temperatures, burning up calories in the process, also 'hoovers up' excess sugar. The findings, published in The Journal of Cell Biology, are significant for people with type 2 diabetes, whose bodies are unable to respond to insulin properly, resulting in elevated blood glucose levels. Researchers believe that if brown fat cells can ...

Football players found to have brain damage from mild 'unreported' concussions

Football players found to have brain damage from mild unreported concussions
2014-11-24
Beer-Sheva, Israel, Nov. 24, 2014 - A new, enhanced MRI diagnostic approach was, for the first time, able to identify significant damage to the blood-brain barrier (BBB) of professional football players following "unreported" trauma or mild concussions. Published in the current issue of JAMA Neurology, this study could improve decision making on when an athlete should "return to play." According to Dr. Alon Friedman, from the Ben-Gurion University Brain Imaging Research Center and discoverer of the new diagnostic, "until now, there wasn't a diagnostic capability to identify ...

Breaking with tradition: The 'personal touch' is key to cultural preservation

2014-11-24
"Memetics," or the study of memes, is a very popular discipline among cultural researchers now, particularly as it concerns new media like viral videos. But no one seems to know what a meme really is. Originally coined by evolutionary biologist Richard Dawkins, the "meme" transfers cultural information much the way that genes inherit biological properties. Pharrell Williams' feel-good hit "Happy" (2013), one of the top-selling singles of all time, is a recent example of a wildly popular meme. Originally tucked away in the soundtrack of the film Despicable Me 2, the song ...

Teens prescribed anti-anxiety or sleep medications more likely to abuse those drugs illegally

2014-11-24
WASHINGTON - Teens prescribed anti-anxiety or sleep medications may be up to 12 times more likely to abuse those drugs illegally than teens who have never received a prescription, often by obtaining additional pills from friends or family members, according to new research published by the American Psychological Association. Based on surveys of more than 2,700 high school and middle school students from the Detroit area, almost 9 percent had been prescribed a potentially addictive benzodiazepine anti-anxiety medication (e.g., Xanax, Valium or Klonopin) or sleep medication ...

Sorting through recycling bins to learn about alcohol use

2014-11-24
COLUMBUS, Ohio - When researchers wanted to verify alcohol-use survey results at a senior housing center, they came up with a novel way to measure residents' drinking: Count the empty bottles in recycling bins. Scientists compared the recycling bin results with two residential surveys gauging drinking habits of people living in a San Diego complex for low-income, older adults. "We were able to check how much the residents said they were drinking with the empty beer, wine and liquor containers they were actually putting in the recycling bins," said John Clapp, co-author ...

Mimics do not substitute for the 'real thing' for bomb-sniffing dogs

2014-11-24
When it comes to teaching dogs how to sniff out explosives, there's nothing quite like the real thing to make sure they're trained right. That's the message from William Kranz, Nicholas Strange and John Goodpaster of Indiana University-Purdue University Indianapolis (IUPUI) in the US, after finding that dogs that are trained with so-called "pseudo-explosives" could not reliably sniff out real explosives (and vice versa). Their findings are published online in Springer's journal Analytical and Bioanalytical Chemistry. Genuine explosive materials are traditionally used ...

LAST 30 PRESS RELEASES:

Scientists model 'true prevalence' of COVID-19 throughout pandemic

New breakthrough to help immune systems in the fight against cancer

Through the thin-film glass, researchers spot a new liquid phase

Administering opioids to pregnant mice alters behavior and gene expression in offspring

Brain's 'memory center' needed to recognize image sequences but not single sights

Safety of second dose of mRNA COVID-19 vaccines after first-dose allergic reactions

Changes in disparities in access to care, health after Medicare eligibility

Use of high-risk medications among lonely older adults

65+ and lonely? Don't talk to your doctor about another prescription

Exosome formulation developed to deliver antibodies for choroidal neovascularization therapy

Second COVID-19 mRNA vaccine dose found safe following allergic reactions to first dose

Plant root-associated bacteria preferentially colonize their native host-plant roots

Rare inherited variants in previously unsuspected genes may confer significant risk for autism

International experts call for a unified public health response to NAFLD and NASH epidemic

International collaboration of scientists rewrite the rulebook of flowering plant genetics

Improving air quality reduces dementia risk, multiple studies suggest

Misplaced trust: When trust in science fosters pseudoscience

Two types of blood pressure meds prevent heart events equally, but side effects differ

New statement provides path to include ethnicity, ancestry, race in genomic research

Among effective antihypertensive drugs, less popular choice is slightly safer

Juicy past of favorite Okinawan fruit revealed

Anticipate a resurgence of respiratory viruses in young children

Anxiety, depression, burnout rising as college students prepare to return to campus

Goal-setting and positive parent-child relationships reduce risk of youth vaping

New research identifies cancer types with little survival improvements in adolescents and young adul

Oncotarget: Replication-stress sensitivity in breast cancer cells

Oncotarget: TERT and its binding protein: overexpression of GABPA/B in gliomas

Development of a novel technology to check body temperature with smartphone camera

The mechanics of puncture finally explained

Extreme heat, dry summers main cause of tree death in Colorado's subalpine forests

[Press-News.org] High-dose interleukin-2 effective in mRCC pre-treated with VEGF-targeted therapies
ESMO Symposium on Immuno-Oncology 2014